Funding secured for the next step of BioC clinical plan
The interest was very high and a new issue of 14M SEK was oversubscribed. The money will be used for the clinical phase Ib study on patient with complex wounds and for preparation of the clinical trial phase II.
Xinnate is awarded a prestigious grant from the US Department of Defense
Xinnate is awarded prestigious grant from the US Department of Defense (DoD) of 1,77M USD over three years. The grant was issued by US Army Medical Research Acquisition Activity (USAMRAA) and will be used for development of a BioC based formulation in the project entitled ”Prevention and Treatment of Infection and Inflammation in Pressure Ulcers”. The project will run in parallel with the clinical work on acute wounds.
Martin Malmsten, Professor in Biopharmaceuticals, Biophysics and Drug Delivery at the University of Copenhagen and the Director of LEO Foundation Center for Cutaneous Drug Delivery, has taken on the role as Sr advisor and will support the project.